Key terms
About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IONS news
Apr 09
7:06am ET
Ionis Pharmaceuticals (IONS) Gets a Buy from Piper Sandler
Apr 09
7:00am ET
Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)
Apr 08
7:40pm ET
Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)
Apr 08
7:15am ET
Stifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)
Apr 08
6:06am ET
Ionis Pharmaceuticals Faces Sell Rating Amid Weak Clinical Results and Rising Competition
Apr 08
5:50am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ionis Pharmaceuticals (IONS) and Medtronic (MDT)
Apr 08
5:47am ET
Buy Rating on Ionis Pharmaceuticals: Promising Clinical Data and Strategic Market Positioning for Olezarsen
Apr 07
4:04pm ET
Ionis Pharmaceuticals presents results from Phase 3 Balance study olezarsen
Apr 03
5:55am ET
Ionis Pharmaceuticals management to meet with Piper Sandler
Apr 02
4:55am ET
Ionis Pharmaceuticals management to meet with Piper Sandler
Mar 28
10:40am ET
Ionis Pharmaceuticals management to meet with Piper Sandler
Mar 25
8:28am ET
Ionis Pharmaceuticals to present data from Phase 3 on olezarsen
Mar 18
7:50am ET
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Edwards Lifesciences (EW) and Aveanna Healthcare Holdings (AVAH)
Mar 14
7:36am ET
TD Cowen Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Mar 14
5:50am ET
Analysts Offer Insights on Healthcare Companies: Chemed (CHE), Ionis Pharmaceuticals (IONS) and Arcellx Inc (ACLX)
Mar 13
7:10am ET
Ionis announces results from Phase 2 study of ION224
Mar 06
8:17am ET
Ionis Pharmaceuticals price target raised to $72 from $65 at Oppenheimer
Mar 06
8:00am ET
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Ionis Pharmaceuticals (IONS) and Fusion Pharmaceuticals (FUSN)
Mar 06
7:37am ET
TD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
Feb 29
9:22am ET
Ionis Pharmaceuticals Announces Executive Advisory and Leadership Changes
Feb 29
9:11am ET
Ionis Pharma names Kyle Jenne new Chief Global Product Strategy Officer
Feb 29
5:37am ET
Ionis Pharmaceuticals: A Strong Buy on Robust Clinical Program Developments and Competitive Advantages
Feb 26
8:05am ET
Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Feb 25
11:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Feb 22
8:11am ET
Ionis Pharmaceuticals price target raised to $63 from $62 at Piper Sandler
Feb 22
8:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Silver Spike Investment (SSIC) and Ionis Pharmaceuticals (IONS)
Feb 22
7:38am ET
Ionis Pharmaceuticals: A Strong Buy on ATTR Franchise Prospects and Financial Fortitude
Feb 22
7:32am ET
RBC Capital Remains a Buy on Ionis Pharmaceuticals (IONS)
Feb 22
5:40am ET
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Ionis Pharmaceuticals (IONS) and Icon (ICLR)
Feb 22
5:07am ET
Barclays Remains a Hold on Ionis Pharmaceuticals (IONS)
Feb 21
5:05pm ET
Ionis Pharmaceuticals: A Buy Rating Based on Strong Q4 Earnings, Promising Pipeline, and Strategic Market Expansion
No recent press releases are available for IONS
IONS Financials
Key terms
Ad Feedback
IONS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IONS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range